公开(公告)号：US20240059677A1

公开(公告)日：2024-02-22

申请号：US18025315

申请日：2021-09-10

Applicant: Cerevance, Inc. ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Roland Werner Burli ,  Martin Teall ,  Nicola Brice

IPC: C07D403/12 ,  C07D401/12 ,  A61K45/06

CPC classification number: C07D403/12 ,  C07D401/12 ,  A61K45/06 ,  C07B2200/05 ,  C07B2200/07

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity.

公开(公告)号：US20240158385A1

公开(公告)日：2024-05-16

申请号：US18275862

申请日：2022-02-08

Applicant: Cerevance, Inc.

Inventor： Roland Werner Burli ,  Kevin Doyle ,  Martin Teall

IPC: C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for use in treating disorders associated with KCNK13 activity.